We are live on
!
Find out more
Hudson Bay Capital Management Portfolio holdings
AUM
$29B
1-Year Est. Return
30.2%
This Fund
S&P 500
This Quarter
Est. Return
+23.54%
1 Year Est. Return
+30.2%
3 Year Est. Return
+99.99%
5 Year Est. Return
+135.78%
10 Year Est. Return
+498.47%
AUM
$5.72B
AUM Growth
+$1.72B
(+43%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-18.95%
Top 10 Holdings %
Top 10 Hldgs %
42.77%
Holding
683
New
195
Increased
120
Reduced
90
Closed
196
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Legend Biotech
LEGN
|
+$119M |
| 2 |
DraftKings
DKNG
|
+$63.9M |
| 3 |
NKLA
Nikola Corporation Common Stock
NKLA
|
+$49.9M |
| 4 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$45.5M |
| 5 |
CTEV
Claritev Corp
CTEV
|
+$42.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$187M |
| 2 |
CCXX.U
Churchill Capital Corp III Units, each consisting of one share of Class A Common Stock and one-fourt
CCXX.U
|
+$43.2M |
| 3 |
Tesla
TSLA
|
+$38.7M |
| 4 |
Amazon
AMZN
|
+$37M |
| 5 |
CFFAU
CF Finance Acquisition Corp. Unit
CFFAU
|
+$27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 13.08% |
| 2 | Communication Services | 9.75% |
| 3 | Consumer Discretionary | 8.87% |
| 4 | Financials | 5.61% |
| 5 | Industrials | 3.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
State Street SPDR S&P 500 ETF Trust
SPY
$807B
| $1.85M | 0.03% |
6,000
-44,714
| -88% | -$13.1M |
|
302
RB Global
RBA
$16.6B
| $1.85M | 0.03% |
+45,250
| New | +$1.85M |
|
303
Ross Stores
ROST
$80.8B
| $1.81M | 0.03% |
+21,200
| New | +$1.92M |
|
|
ARNA
304
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.79M | 0.03% |
28,500
-1,500
| -5% | -$82.5K |
|
305
Arbutus Biopharma
ABUS
$923M
| $1.77M | 0.03% |
975,000
+175,000
| +22% | +$286K |
|
306
Cardlytics
CDLX
$22.4M
| $1.75M | 0.03% |
+2,500
| New | +$1.44M |
|
307
Roku
ROKU
$22.4B
| $1.75M | 0.03% |
+15,000
| New | +$1.72M |
|
|
DOOR
308
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $1.74M | 0.03% |
22,330
-7,657
| -26% | -$465K |
|
|
ACEL.WS
309
DELISTED
Accel Entertainment Inc Warrant
ACEL.WS
| $1.64M | 0.03% |
701,724
| – | – |
|
|
LVOX
310
DELISTED
LiveVox Holding, Inc. Class A Common Stock
LVOX
| $1.62M | 0.03% |
155,000
-25,000
| -14% | -$252K |
|
311
Royal Caribbean
RCL
$82.1B
| $1.61M | 0.03% |
32,000
-23,500
| -42% | -$1.06M |
|
312
National CineMedia
NCMI
$355M
| $1.56M | 0.03% |
+52,631
| New | +$1.58M |
|
313
National Vision
EYE
$1.77B
| $1.56M | 0.03% |
+51,150
| New | +$1.34M |
|
314
Lithia Motors
LAD
$8.32B
| $1.53M | 0.03% |
+10,114
| New | +$1.16M |
|
|
TCO
315
DELISTED
Taubman Centers Inc.
TCO
| $1.51M | 0.03% |
+40,138
| New | +$1.64M |
|
316
Arrowhead Research
ARWR
$12.6B
| $1.51M | 0.03% |
+35,000
| New | +$1.24M |
|
|
NVCN
317
DELISTED
Neovasc Inc.
NVCN
| $1.5M | 0.03% |
+25,277
| New | +$1.58M |
|
318
Immunic
IMUX
$211M
| $1.49M | 0.03% |
+12,305
| New | +$1.25M |
|
|
OPTN
319
DELISTED
OptiNose
OPTN
| $1.49M | 0.03% |
13,333
-1,667
| -11% | -$119K |
|
320
CALL
Acadia Pharmaceuticals
ACAD
$5.07B
| $1.45M | 0.03% |
+30,000
| New | +$1.44M |
|
321
Krystal Biotech
KRYS
$9.68B
| $1.45M | 0.03% |
+35,000
| New | +$1.68M |
|
322
Exelixis
EXEL
$12.7B
| $1.42M | 0.02% |
60,000
| – | – |
|
323
Datadog
DDOG
$88.6B
| $1.41M | 0.02% |
16,200
-67,300
| -81% | -$4.1M |
|
|
EA
324
DELISTED
Electronic Arts
EA
| $1.39M | 0.02% |
10,500
-14,500
| -58% | -$1.71M |
|
325
Abeona Therapeutics
ABEO
$422M
| $1.38M | 0.02% |
19,000
+10,000
| +111% | +$691K |
|
Similar funds
PCH
N
TWC
FDCDDQ
Hudson Bay Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Hudson Bay Capital Management held 683 positions worth $5.72B, up 43% from $3.99B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Hudson Bay Capital Management withdrew a net $1.08B in Q2 2020, closing 196 positions and reducing 90 holdings. Its most notable exit was Allergan plc, an estimated $187M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 13% a quarter earlier, followed by Communication Services and Consumer Discretionary.
Against the trend, Hudson Bay Capital Management opened a new position in Legend Biotech worth $122M.
- Hudson Bay Capital Management's largest Q2 2020 buy was Legend Biotech: 3,056,342 shares worth $122M.
- Hudson Bay Capital Management added most to DraftKings in Q2 2020, an estimated $63.9M increase.
- Hudson Bay Capital Management's biggest Q2 2020 reduction was Tesla, cutting an estimated $38.7M.
- Hudson Bay Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $187M.
- Hudson Bay Capital Management's ten largest holdings make up 43% of its $5.72B portfolio in Q2 2020.
- Hudson Bay Capital Management opened 195 new positions and closed 196 in Q2 2020.
- Hudson Bay Capital Management's portfolio value rose 43% quarter-over-quarter to $5.72B.
Based on Hudson Bay Capital Management's 13F filing for Q2 2020, filed 12 Aug 2020.